published meta-analysis   sensitivity analysis   studies

standard of care in COVID-19 severe or critically - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsCOALITION II Covid-19 Brazil (Furtado), 2020 (REV) 0.93 [0.68; 1.26] 0.93[0.68; 1.26]COALITION II Covid-19 Brazil (Furtado), 2020 (REV)10%397NAnot evaluable deathsdetailed resultsCOALITION II Covid-19 Brazil (Furtado), 2020 (REV) 0.93 [0.68; 1.26] 0.93[0.68; 1.26]COALITION II Covid-19 Brazil (Furtado), 2020 (REV)10%397NAnot evaluable deaths (time to event analysis only)detailed resultsCOALITION II Covid-19 Brazil (Furtado), 2020 (REV) 0.93 [0.68; 1.26] 0.93[0.68; 1.26]COALITION II Covid-19 Brazil (Furtado), 2020 (REV)10%397NAnot evaluable clinical improvementdetailed resultsCOALITION II Covid-19 Brazil (Furtado), 2020 (REV) 1.35 [0.94; 1.95] 1.35[0.94; 1.95]COALITION II Covid-19 Brazil (Furtado), 2020 (REV)10%397NAnot evaluable clinical improvement (14-day)detailed resultsCOALITION II Covid-19 Brazil (Furtado), 2020 (REV) 1.35 [0.94; 1.95] 1.35[0.94; 1.95]COALITION II Covid-19 Brazil (Furtado), 2020 (REV)10%397NAnot evaluable clinical improvement (28-day)detailed resultsCOALITION II Covid-19 Brazil (Furtado), 2020 (REV) 1.43 [0.96; 2.13] 1.43[0.96; 2.13]COALITION II Covid-19 Brazil (Furtado), 2020 (REV)10%397NAnot evaluable clinical improvement (7-day)detailed resultsCOALITION II Covid-19 Brazil (Furtado), 2020 (REV) 1.06 [0.71; 1.58] 1.06[0.71; 1.58]COALITION II Covid-19 Brazil (Furtado), 2020 (REV)10%397NAnot evaluable related SAE (TRSAE)detailed resultsCOALITION II Covid-19 Brazil (Furtado), 2020 (REV) 0.80 [0.32; 2.01] 0.80[0.32; 2.01]COALITION II Covid-19 Brazil (Furtado), 2020 (REV)10%439NAnot evaluable serious adverse eventsdetailed resultsCOALITION II Covid-19 Brazil (Furtado), 2020 (REV) 0.83 [0.57; 1.22] 0.83[0.57; 1.22]COALITION II Covid-19 Brazil (Furtado), 2020 (REV)10%439NAnot evaluable long QTdetailed resultsCOALITION II Covid-19 Brazil (Furtado), 2020 (REV) 1.11 [0.70; 1.77] 1.11[0.70; 1.77]COALITION II Covid-19 Brazil (Furtado), 2020 (REV)10%439NAnot evaluable renal impairmentdetailed resultsCOALITION II Covid-19 Brazil (Furtado), 2020 (REV) 0.69 [0.47; 1.01] 0.69[0.47; 1.01]COALITION II Covid-19 Brazil (Furtado), 2020 (REV)10%439NAnot evaluable0.52.01.0relative treatment effectwww.metaEvidence.org2024-06-12 11:15 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 91 - treatments: 651 - roots T: 651